Comparative Pharmacology
Head-to-head clinical analysis: PIFELTRO versus RILPIVIRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIFELTRO versus RILPIVIRINE.
PIFELTRO vs RILPIVIRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective allosteric inhibitor of HIV-1 capsid protein, interfering with multiple steps of the viral life cycle including capsid assembly, nuclear import, and virion maturation.
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase, causing a conformational change that inhibits the enzyme's activity and prevents viral RNA-dependent DNA polymerization.
200 mg orally once daily, taken with or without food.
25 mg orally once daily with a meal.
None Documented
None Documented
12-13 hours in healthy subjects; clinically, supports once-daily dosing.
Clinical Note
moderateRilpivirine + Levofloxacin
"The serum concentration of Levofloxacin can be increased when it is combined with Rilpivirine."
Clinical Note
moderateRilpivirine + Norfloxacin
"The serum concentration of Norfloxacin can be increased when it is combined with Rilpivirine."
Clinical Note
moderateRilpivirine + Prednisolone
"The serum concentration of Prednisolone can be increased when it is combined with Rilpivirine."
Clinical Note
moderateRilpivirine + Resveratrol
Terminal elimination half-life is approximately 50 hours (range 41–55 h), supporting once-daily dosing.
Primarily hepatic metabolism with subsequent biliary/fecal elimination. 86% of a single oral dose recovered in feces (mostly as metabolites) and <1% unchanged in urine.
Renal (1% unchanged, 6% as metabolites); Fecal (85% as metabolites, 25% unchanged)
Category C
Category A/B
NNRTI
NNRTI
"The serum concentration of Resveratrol can be increased when it is combined with Rilpivirine."